US › Healthcare

Evotec SE ADR (EVO)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.95+0.52%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$159.2M
Revenue YoY
-20.4%
Net profit
$-123.9M
Profit YoY
-292.5%
EPS
$-0.34
EPS estimate
$-0.17
Net margin
-77.8%

EPS came in at -0.34 against a street estimate of -0.17 — a miss of 100.0%.

Key statistics

Market cap
$678.8M
Forward P/E
53.5
P/B
0.85
Book value
$2.27
EPS (TTM)
$-0.63
52-week high
$4.27
52-week low
$1.90
50-day MA
$2.57
200-day MA
$3.05
Beta
1.31

Analyst view

Analysts rate Evotec SE ADR a buy (4 buy, 1 hold, 1 sell out of 6) with an average price target of $3.83.

Shareholding

Insiders
0.01%
Institutions
2.15%

Largest institutional holders

FundStake
Mubadala Investment Company PJSC1.29%
DCF Advisers, LLC0.30%
WCM Investment Management0.18%
ABC arbitrage SA0.10%
Optiver Holding B.V.0.08%
Morgan Stanley - Brokerage Accounts0.07%
LPL Financial Corp0.03%
Millennium Management LLC0.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Evotec SE ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.